Overview

Study to Evaluate the Antiviral Activity of Inarigivir Soproxil (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)

Status:
Completed

Trial end date:
2021-01-26

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the safety and tolerability of the 12 week treatment regimens of inarigivir soproxil (GS-9992) plus tenofovir alafenamide (TAF) or commercially available nucleoside/nucleotide (NUC) in adults with chronic hepatitis B (CHB), to evaluate the antiviral activity of 12 weeks of inarigivir soproxil plus TAF versus TAF alone in viremic CHB participants (Groups 1-3, 5), and to evaluate the antiviral activity of 12 weeks of inarigivir soproxil with commercially available NUC(s) in virally suppressed CHB participants (Group 4).

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Collaborators:

F-star Therapeutics, Inc.
Spring Bank Pharmaceuticals, Inc.

Treatments:

Antiviral Agents
Tenofovir